Selank vs Semax: Comparación de péptidos nootrópicos

Introduction: Two Pillars of Russian Peptide Neuroscience

Selank and Semax are synthetic peptides developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, representing two of the most significant contributions of Russian peptide science to the nootropic research field. Both were developed under the direction of Nikolai Myasoedov and have been approved as medications in Russia, though they remain unapproved and largely unavailable through conventional channels in Western countries.

Despite sharing a common institutional origin and similar research trajectories, Selank and Semax target different neurological domains: Selank was designed primarily as an anxiolytic, while Semax was developed as a cognitive enhancer and neuroprotective agent. This comparison examines the research supporting each compound and clarifies their distinct profiles.

For a combined overview, see our article on Selank and Semax Regulatory Peptides. For broader context, see Nootropic Peptides Overview.

Comparison Table

Property	Selank	Semax
Parent Molecule	Tuftsin (Thr-Lys-Pro-Arg) — immune peptide	ACTH(4-10) (Met-Glu-His-Phe-Pro-Gly-Pro) — adrenocorticotropic fragment
Full Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro (tuftsin + Pro-Gly-Pro)	Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 with C-terminal Pro-Gly-Pro)
Primary Effect	Anxiolytic (anti-anxiety)	Nootropic (cognitive enhancement)
Secondary Effects	Immune modulation, mild nootropic	Neuroprotective, mild anxiolytic at lower doses
Key Neurotransmitter Systems	GABAergic, serotonergic (5-HT), enkephalin metabolism	Dopaminergic, serotonergic, BDNF/NGF expression
BDNF Effects	Moderate upregulation	Strong upregulation (primary mechanism)
Administration	Intranasal (primary), subcutaneous	Intranasal (primary), subcutaneous
Half-Life	Several minutes (but effects last hours due to downstream signaling)	Several minutes (Pro-Gly-Pro extension improves stability)
Russian Approval	Yes — anxiolytic nasal spray	Yes — nootropic nasal spray and stroke treatment
FDA Status	Not approved	Not approved
Addiction/Dependence Potential	None documented in research	None documented in research
Cortisol/Hormonal Effects	No significant hormonal effects	Does not raise cortisol (despite ACTH origin)

Mechanisms: Different Pathways, Different Outcomes

Selank: The Anxiolytic Pathway

Selank's anxiolytic effects are mediated through several interconnected mechanisms. Research has demonstrated that Selank influences the GABAergic system, the primary inhibitory neurotransmitter network in the brain. Specifically, Selank appears to modulate GABA receptor sensitivity and may influence the metabolism of GABA in the synaptic cleft.

Additionally, Selank has been shown to inhibit the enzymes that degrade enkephalins, the body's endogenous opioid peptides. By prolonging enkephalin activity, Selank may produce anxiolytic effects similar to, but mechanistically distinct from, benzodiazepines. Importantly, unlike benzodiazepines, Selank does not appear to produce sedation, cognitive impairment, or dependence in the studies conducted to date.

Selank also influences the serotonergic system, with research showing effects on serotonin metabolism in the hypothalamus and other brain regions. This dual GABAergic-serotonergic mechanism may explain its reported ability to reduce anxiety without the cognitive side effects associated with purely GABAergic drugs.

A unique aspect of Selank is its immunomodulatory heritage. Derived from tuftsin, an immune-activating peptide, Selank retains some immune-modulating properties, including effects on cytokine expression and immune cell function. This dual neuro-immune profile is unusual among anxiolytic compounds.

Semax: The Nootropic Pathway

Semax's cognitive-enhancing effects center on its ability to upregulate brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), two critical proteins involved in neuronal survival, growth, and synaptic plasticity. Research in animal models has shown that Semax administration increases BDNF expression in the hippocampus and cortex, brain regions essential for learning and memory.

Despite being derived from ACTH (adrenocorticotropic hormone), Semax does not stimulate cortisol production. The ACTH(4-10) fragment used as Semax's backbone represents the "nootropic" portion of ACTH that influences cognitive function without engaging the adrenal cortex. This dissociation of cognitive effects from hormonal effects was a deliberate design goal.

Semax also modulates the dopaminergic system, particularly in the prefrontal cortex, which may contribute to its effects on attention, working memory, and executive function. Research has shown increased expression of tyrosine hydroxylase (the rate-limiting enzyme in dopamine synthesis) following Semax administration.

Neuroprotective effects of Semax have been studied in stroke and traumatic brain injury models, where it has shown ability to reduce infarct volume and improve functional recovery. This led to its approval in Russia as a treatment for stroke and transient ischemic attacks.

Best Research Applications

Winner for Anxiety Research: Selank

Selank's primary profile is anxiolytic. For research examining anti-anxiety effects, GABA modulation, or stress-related behavioral changes, Selank is the more appropriate compound. Its lack of sedation and dependence potential make it particularly interesting for anxiety research contexts where those side effects are problematic.

Winner for Cognitive Enhancement Research: Semax

For research focused on learning, memory, attention, or cognitive performance, Semax has the stronger evidence base. Its robust BDNF upregulation and dopaminergic modulation provide well-characterized mechanisms relevant to cognitive function.

Winner for Neuroprotection Research: Semax

Semax's clinical use in stroke treatment in Russia and its preclinical evidence in brain injury models make it the stronger candidate for neuroprotection research. The BDNF and NGF upregulation mechanisms are directly relevant to neuronal survival and recovery.

Winner for Immune-Neuro Crossover Research: Selank

Selank's unique dual profile as both an anxiolytic and an immunomodulator makes it valuable for research exploring the intersection of immune function and neurological state, an increasingly important area of neuroscience.

Can They Be Combined?

Some researchers have explored the combination of Selank and Semax, reasoning that the anxiolytic effects of Selank and the cognitive-enhancing effects of Semax may be complementary. While dedicated combination studies are limited, the non-overlapping primary mechanisms suggest theoretical compatibility. However, this remains an area requiring further formal investigation.